Kiryat Ata, Israel

Ira Bavli-kertselli

This inventor holds 1 USPTO granted patent. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ira Bavli-kertselli. Retrieved from https://idiyas.com/inventor/ira-bavli-kertselli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ira Bavli-Kertselli: Innovator in Pharmaceutical Compositions

Introduction

Ira Bavli-Kertselli is a notable inventor based in Kiryat Ata, Israel. He has made significant contributions to the field of pharmaceutical compositions, particularly in relation to diseases associated with ApoL1. His innovative work has led to the development of a patent that addresses critical health issues.

Latest Patents

Ira Bavli-Kertselli holds a patent for a composition intended for the treatment of ApoL1-associated diseases. This invention encompasses various embodiments that relate to compositions and/or pharmaceutical compositions containing one or more biologically active compounds. The patent is directed towards methods of using these compositions for treating disorders related to ApoL1 in subjects. He has 1 patent to his name.

Career Highlights

Ira is currently employed at Vertex Pharmaceuticals, Inc., a leading company in the biotechnology sector. His role at Vertex allows him to further his research and development efforts in creating effective treatments for complex diseases.

Collaborations

Ira has collaborated with esteemed colleagues in his field, including Karl Skorecki and Tali Shemer. Their combined expertise contributes to the advancement of innovative solutions in pharmaceutical research.

Conclusion

Ira Bavli-Kertselli's work exemplifies the impact of innovation in the medical field, particularly through his contributions to treatments for ApoL1-related diseases. His dedication to research and collaboration continues to pave the way for future advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…